进展期胃癌分子靶向治疗的研究进展

胃癌是目前全球癌症死亡的第二大原因，早期诊断困难，传统的手术和放化疗治疗进展期胃癌的有效率低。随着对肿瘤发病机制研究的不断深入，分子靶向治疗成为肿瘤治疗的发展趋势。这些靶向治疗策略主要包括：HER2单克隆抗体、表皮生长因子受体抑制剂、血管生成抑制剂、mTOR抑制剂、细胞周期蛋白依赖性激酶（CDKs）、基质金属蛋白酶（MMPS）抑制剂/c-Met抑制剂/IGF-1R抑制剂/HSP90抑制剂等。本文就进展期胃癌近年来分子靶向治疗的研究结果及相关进展做一综述。

Research progress of molecular targeted therapy for advanced gastric cancer.

Gastric cancer （GC） is currently the second leading cause of cancer death worldwide, and early di-agnosis is difficult and the efficacy of surgery, radiotherapy and chemotherapy for advanced GC is poor. With the deep-ening of study on pathogenesis of tumor, molecular targeted therapy has become a trend for cancer therapy. These ther-apeutic strategies include targeting HER2 monoclonal antibody, EGFR signal transduction pathway, anti-angiogenesis, PI3k/Akt/mTOR pathway inhibitors, multityrosine kinase inhibitors, cyclin dependent kinase （CDK） inhibitors, matrix metalloproteinase inhibitors, c-Met inhibitors, IGF-1R inhibitors and HSP90 inhibitors. This article focuses on summa-rize the most recent the development of targeted therapy for advanced gastric cancer.